Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction
Wenyu Fu, Yujianan Chen, Kaidi Wang, Aubryanna Hettinghouse, Wenhuo Hu, Jing-Quan Wang, Zi‐Ning Lei, Zhe‐Sheng Chen, Kenneth A. Stapleford, Liu C
Abstract
Repurposing FDA-approved drugs for SARS-CoV
Topics & Concepts
RepurposingDrug repositioningSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)PharmacologyDrug approval2019-20 coronavirus outbreakApproved drugMedicineDrugVirologyBiologyInternal medicineInfectious disease (medical specialty)EcologyDiseaseOutbreakComputational Drug Discovery MethodsCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research